Wild Horseshoe Crab Conservation and Biomedical Use

Horseshoe crabs are harvested for biomedical limulus amebocyte lysate (LAL) used in drug safety testing, raising welfare concerns about bleeding practices and mortality.

Key Facts

Horseshoe crab blood contains limulus amebocyte lysate (LAL) used to detect bacterial endotoxins
An estimated 500,000 horseshoe crabs are bled annually in the US biomedical industry
Mortality rates from the bleeding process are estimated at 10-15% by some studies
Horseshoe crabs are a keystone species, with their eggs essential for migratory shorebird survival
A synthetic recombinant Factor C test is available as a cruelty-free alternative to LAL

Welfare Considerations

Horseshoe crabs bled in biomedical facilities experience the stress of capture, transport, and blood extraction. Mortality from bleeding is significant. Animals returned to the ocean may show reduced activity and altered behaviour. The welfare implications depend on horseshoe crab sentience, which remains uncertain but warrants precaution. The availability of synthetic alternatives that do not require crab harvesting represents an important welfare and conservation advance.

What You Can Do

Support adoption of recombinant Factor C testing as an alternative to LAL in pharmaceutical standards
Advocate for regulatory acceptance of synthetic alternatives by organisations like the US Pharmacopeia
Support horseshoe crab conservation as their eggs are critical for migratory shorebird welfare
Report horseshoe crab beach strandings to conservation monitoring programmes
Raise awareness about horseshoe crab welfare and biomedical use